Current Infectious Disease Reports

, Volume 14, Issue 6, pp 668–675 | Cite as

Emerging Invasive Fungal Diseases in Transplantation

  • Perrine Parize
  • Blandine Rammaert
  • Olivier Lortholary
Transplant and Oncology (MG Ison, Section Editor)


Invasive fungal infections continue to be a major cause of morbidity and mortality in severely immunocompromised transplant patients. Although Candida spp. and Aspergillus spp. represent the majority of identified pathogens, other fungi have become increasingly prevalent among this patient population. Diagnosis and treatment of invasive fungal infections remain a challenge in transplant medicine despite recent major advances. In this review, we will emphasize emerging topics in invasive fungal infections in transplantations that occurred in 2011–2012. The current literature was reviewed to synthesize new trends in epidemiology, recent outbreaks, clinical findings, and advances in diagnostic and therapeutic resources.


Solid organ transplantation Hematopoietic stem cell transplantation Mucormycosis Health-care-associated infection Pneumocystis pneumonia 



P. Parize has received grant support from patient association “Vaincre la mucoviscidose” and travel and accommodation support from Sanofi; B. Rammaert has received honoraria from Gilead and travel and accommodation support from MSD; O. Lortholary is a member of the MSD board, is a consultant for Astellas and Gilead Sciences and received grants speaker's fees from MSD, Astellas, Gilead Sciences and Pfizer.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Pagano L, Akova M, Dimopoulos G, Herbrecht R, Drgona L, Blijlevens N. Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients. J Antimicrob Chemother. 2011;66 Suppl 1:i5–i14.PubMedCrossRefGoogle Scholar
  2. 2.
    •• Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis. 2010;50:1101–11. A major cohort study assessing the overall and organ-specific burden of invasive fungal infections among transplants recipients.PubMedCrossRefGoogle Scholar
  3. 3.
    •• Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis. 2010;50:1091–100. A major prospective study reporting epidemiologic trends of invasive fungal diseases in hematopoietic stem cell transplant recipients.PubMedCrossRefGoogle Scholar
  4. 4.
    • Lanternier F, Sun H-Y, Ribaud P, Singh N, Kontoyiannis DP, Lortholary O. Mucormycosis in organ and stem cell transplant recipients. Clin Infect Dis. 2012;54:1–8. A recent literature review in addition to authors’ perspectives on mucormycosis occurring in transplant recipients. CrossRefGoogle Scholar
  5. 5.
    Park BJ, Pappas PG, Wannemuehler KA, et al. Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006. Emerging Infect Dis. 2011;17:1855–64.PubMedCrossRefGoogle Scholar
  6. 6.
    Skiada A, Pagano L, Groll A, et al. Zygomycosis in Europe: Analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect 2011; Available at: Accessed 2 March 2011.
  7. 7.
    Lanternier F, Dannaoui E, Morizot G, et al. A Global Analysis of Mucormycosis in France: The RetroZygo Study (2005-2007). Clin Infect Dis. 2012;54:S35–43.PubMedCrossRefGoogle Scholar
  8. 8.
    Spellberg B, Kontoyiannis DP, Fredricks D, et al. Risk factors for mortality in patients with mucormycosis. Med Mycol 2012; Available at: Accessed 22 May 2012.
  9. 9.
    Spellberg B, Ibrahim AS, Chin-Hong PV, et al. The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. J Antimicrob Chemother. 2012;67:715–22.PubMedCrossRefGoogle Scholar
  10. 10.
    Zaoutis TE, Webber S, Naftel DC, et al. Invasive fungal infections in pediatric heart transplant recipients: incidence, risk factors, and outcomes. Pediatr Transplant. 2011;15:465–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Ng B, Dipchand A, Naftel D, et al. Outcomes of Pneumocystis jiroveci pneumonia infections in pediatric heart transplant recipients. Pediatr Transplant. 2011;15:844–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Däbritz J, Attarbaschi A, Tintelnot K, et al. Mucormycosis in paediatric patients: demographics, risk factors and outcome of 12 contemporary cases. Mycoses. 2011;54:e785–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Rammaert B, Lanternier F, Zahar J-R, et al. Healthcare-Associated Mucormycosis. Clin Infect Dis. 2012;54:S44–54.PubMedCrossRefGoogle Scholar
  14. 14.
    Choukri F, Menotti J, Sarfati C, et al. Quantification and spread of Pneumocystis jirovecii in the surrounding air of patients with Pneumocystis pneumonia. Clin Infect Dis. 2010;51:259–65.PubMedCrossRefGoogle Scholar
  15. 15.
    European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.7.1 Late infections. Pneumocystis carinii pneumonia. Nephrol. Dial. Transplant. 2002; 17 Suppl 4:36–39.Google Scholar
  16. 16.
    Martin SI, Fishman JA. Pneumocystis pneumonia in solid organ transplant recipients. Am J Transplant. 2009;9 Suppl 4:S227–33.PubMedCrossRefGoogle Scholar
  17. 17.
    Phipps LM, Chen SC-A, Kable K, et al. Nosocomial Pneumocystis jirovecii pneumonia: lessons from a cluster in kidney transplant recipients. Transplantation. 2011;92:1327–34.PubMedCrossRefGoogle Scholar
  18. 18.
    • de Boer MGJ, Kroon FP, le Cessie S, de Fijter JW, van Dissel JT. Risk factors for Pneumocystis jirovecii pneumonia in kidney transplant recipients and appraisal of strategies for selective use of chemoprophylaxis. Transpl Infect Dis. 2011;13:559–69. A study reviewing 16 recent outbreaks of Pneumocystis jirovecii pneumonia in kidney recipients and describing epidemiological characteristics and clinical risk factors for the disease.PubMedCrossRefGoogle Scholar
  19. 19.
    • Emergence of Cryptococcus gattii--Pacific Northwest, 2004-2010. Am. J. Transplant. 2011;11:1989–1992. An article that analyzes the occurrence of two major cryptococcal outbreaks in North America. Google Scholar
  20. 20.
    MacDougall L, Fyfe M, Romney M, Starr M, Galanis E. Risk factors for Cryptococcus gattii infection, British Columbia. Canada Emerging Infect Dis. 2011;17:193–9.CrossRefGoogle Scholar
  21. 21.
    Harris JR, Lockhart SR, Debess E, et al. Cryptococcus gattii in the United States: clinical aspects of infection with an emerging pathogen. Clin Infect Dis. 2011;53:1188–95.PubMedCrossRefGoogle Scholar
  22. 22.
    Limaye AP, Connolly PA, Sagar M, et al. Transmission of Histoplasma capsulatum by organ transplantation. N Engl J Med. 2000;343:1163–6.PubMedCrossRefGoogle Scholar
  23. 23.
    Wright PW, Pappagianis D, Wilson M, et al. Donor-related coccidioidomycosis in organ transplant recipients. Clin Infect Dis. 2003;37:1265–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Mueller NJ, Weisser M, Fehr T, et al. Donor-derived aspergillosis from use of a solid organ recipient as a multiorgan donor. Transpl Infect Dis. 2010;12:54–9.PubMedCrossRefGoogle Scholar
  25. 25.
    Albano L, Bretagne S, Mamzer-Bruneel M-F, et al. Evidence that graft-site candidiasis after kidney transplantation is acquired during organ recovery: a multicenter study in France. Clin Infect Dis. 2009;48:194–202.PubMedCrossRefGoogle Scholar
  26. 26.
    Baddley JW, Schain DC, Gupte AA, et al. Transmission of Cryptococcus neoformans by Organ Transplantation. Clin Infect Dis. 2011;52:e94–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Fishman JA, Greenwald MA, Grossi PA. Transmission of Infection With Human Allografts: Essential Considerations in Donor Screening. Clin Infect Dis 2012; Available at: Accessed 17 July 2012.
  28. 28.
    Greenwald MA, Kuehnert MJ, Fishman JA. Infectious Disease Transmission during Organ and Tissue Transplantation. Emerging Infect Dis. 2012;18:e1.PubMedCrossRefGoogle Scholar
  29. 29.
    • Hot A, Maunoury C, Poiree S, et al. Diagnostic contribution of positron emission tomography with [18F]fluorodeoxyglucose for invasive fungal infections. Clin Microbiol Infect. 2011;17:409–17. The first prospective study on PET scan in various invasive fungal diseases.PubMedCrossRefGoogle Scholar
  30. 30.
    Schmidt S, Tramsen L, Perkhofer S, et al. Characterization of the Cellular Immune Responses to Rhizopus oryzae With Potential Impact on Immunotherapeutic Strategies in Hematopoietic Stem Cell Transplantation. J Infect Dis 2012; Available at: Accessed 22 May 2012.
  31. 31.
    Schrödl W, Heydel T, Schwartze VU, et al. Direct analysis and identification of pathogenic Lichtheimia species by matrix-assisted laser desorption ionization-time of flight analyzer-mediated mass spectrometry. J Clin Microbiol. 2012;50:419–27.PubMedCrossRefGoogle Scholar
  32. 32.
    Coulibaly O, Marinach-Patrice C, Cassagne C, Piarroux R, Mazier D, Ranque S. Pseudallescheria/Scedosporium complex species identification by Matrix-Assisted Laser Desorption Ionization Time-Of-Flight Mass Spectrometry. Med Mycol. 2011;49:621–6.PubMedGoogle Scholar
  33. 33.
    Hammond SP, Bialek R, Milner DA, Petschnigg EM, Baden LR, Marty FM. Molecular methods to improve diagnosis and identification of mucormycosis. J Clin Microbiol. 2011;49:2151–3.PubMedCrossRefGoogle Scholar
  34. 34.
    Babady NE, Miranda E, Gilhuley KA. Evaluation of Luminex xTAG fungal analyte-specific reagents for rapid identification of clinically relevant fungi. J Clin Microbiol. 2011;49:3777–82.PubMedCrossRefGoogle Scholar
  35. 35.
    Steinmann J, Schmidt D, Buer J, Rath P-M. Discrimination of Scedosporium prolificans against Pseudallescheria boydii and Scedosporium apiospermum by semiautomated repetitive sequence-based PCR. Med Mycol. 2011;49:475–83.PubMedGoogle Scholar
  36. 36.
    Lu Q, Gerrits van den Ende AH, Bakkers JM, et al. Identification of Pseudallescheria and Scedosporium species by three molecular methods. J Clin Microbiol. 2011;49:960–7.PubMedCrossRefGoogle Scholar
  37. 37.
    De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46:1813–21.PubMedCrossRefGoogle Scholar
  38. 38.
    • Lamoth F, Cruciani M, Mengoli C, et al. β-Glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the Third European Conference on Infections in Leukemia (ECIL-3). Clin Infect Dis. 2012;54:633–43. A meta-analysis reporting the performance of BG antigenemia assays for the diagnosis of invasive fungal infections in patients with hematological malignancies.PubMedCrossRefGoogle Scholar
  39. 39.
    de Boer MGJ, Gelinck LBS, van Zelst BD, et al. β-D-glucan and S-adenosylmethionine serum levels for the diagnosis of Pneumocystis pneumonia in HIV-negative patients: a prospective study. J Infect. 2011;62:93–100.PubMedCrossRefGoogle Scholar
  40. 40.
    Costa J-M, Botterel F, Cabaret O, Foulet F, Cordonnier C, Bretagne S. Association Between Circulating DNA, Serum (1- > 3)-β-D-Glucan, and Pulmonary Fungal Burden in Pneumocystis Pneumonia. Clin Infect Dis. 2012;55:e5–8.PubMedCrossRefGoogle Scholar
  41. 41.
    Hauser PM, Bille J, Lass-Flörl C, et al. Multicenter, prospective clinical evaluation of respiratory samples from subjects at risk for Pneumocystis jirovecii infection by use of a commercial real-time PCR assay. J Clin Microbiol. 2011;49:1872–8.PubMedCrossRefGoogle Scholar
  42. 42.
    Kontoyiannis DP, Lewis RE, Lotholary O, et al. Future directions in mucormycosis research. Clin Infect Dis. 2012;54 Suppl 1:S79–85.PubMedCrossRefGoogle Scholar
  43. 43.
    Kontoyiannis DP, Lewis RE. How I treat mucormycosis. Blood. 2011;118:1216–24.PubMedCrossRefGoogle Scholar
  44. 44.
    Lewis RE, Leventakos K, Liao G, Kontoyiannis DP. Efficacy of caspofungin in neutropenic and corticosteroid-immunosuppressed murine models of invasive pulmonary mucormycosis. Antimicrob Agents Chemother. 2011;55:3584–7.PubMedCrossRefGoogle Scholar
  45. 45.
    Ibrahim AS, Gebremariam T, Luo G, et al. Combination Therapy of Murine Mucormycosis or Aspergillosis with Iron Chelation, Polyenes and Echinocandins. Antimicrob Agents Chemother 2011; Available at: Accessed 2 March 2011.
  46. 46.
    Drogari-Apiranthitou M, Mantopoulou F-D, Skiada A, et al. In vitro antifungal susceptibility of filamentous fungi causing rare infections: synergy testing of amphotericin B, posaconazole and anidulafungin in pairs. J Antimicrob Chemother. 2012;67:1937–40.PubMedCrossRefGoogle Scholar
  47. 47.
    Vigouroux S, Morin O, Moreau P, et al. Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required. Clin Infect Dis. 2005;40:e35–7.PubMedCrossRefGoogle Scholar
  48. 48.
    Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis. 2005;191:1350–60.PubMedCrossRefGoogle Scholar
  49. 49.
    Lewis RE, Liao G, Wang W, Prince RA, Kontoyiannis DP. Voriconazole pre-exposure selects for breakthrough mucormycosis in a mixed model of Aspergillus fumigatus-Rhizopus oryzae pulmonary infection. Virulence. 2011;2:348–55.PubMedCrossRefGoogle Scholar
  50. 50.
    Potenza L, Vallerini D, Barozzi P, et al. Mucorales-specific T cells emerge in the course of invasive mucormycosis and may be used as a surrogate diagnostic marker in high-risk patients. Blood. 2011;118:5416–9.PubMedCrossRefGoogle Scholar
  51. 51.
    Kontoyiannis DP. Deferasirox lacks in vitro activity against Fusarium and Scedosporium species and black molds. Virulence. 2011;2:257–8.PubMedCrossRefGoogle Scholar
  52. 52.
    Lackner M, Rezusta A, Villuendas MC, Palacian MP, Meis JF, Klaassen CH. Infection and colonisation due to Scedosporium in Northern Spain. An in vitro antifungal susceptibility and molecular epidemiology study of 60 isolates. Mycoses. 2011;54 Suppl 3:12–21.PubMedCrossRefGoogle Scholar
  53. 53.
    Spader TB, Venturini TP, Cavalheiro AS, et al. In vitro interactions between amphotericin B and other antifungal agents and rifampin against Fusarium spp. Mycoses. 2011;54:131–6.PubMedCrossRefGoogle Scholar
  54. 54.
    Lortholary O, Obenga G, Biswas P, et al. International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole. Antimicrob Agents Chemother. 2010;54:4446–50.PubMedCrossRefGoogle Scholar
  55. 55.
    Persy B, Vrelust I, Gadisseur A, Ieven M. Phialemonium curvatum fungaemia in an immunocompromised patient: case report. Acta Clin Belg. 2011;66:384–6.PubMedGoogle Scholar
  56. 56.
    Choi J, Lee Y, Chung H-S, et al. Subcutaneous phaeohyphomycosis caused by Phaeoacremonium species in a kidney transplant patient: the first case in Korea. Korean J Lab Med. 2011;31:201–4.PubMedCrossRefGoogle Scholar
  57. 57.
    Miossec C, Morio F, Lepoivre T, et al. Fatal invasive infection with fungemia due to Microascus cirrosus after heart and lung transplantation in a patient with cystic fibrosis. J Clin Microbiol. 2011;49:2743–7.PubMedCrossRefGoogle Scholar
  58. 58.
    Pelegrín I, Ayats J, Xiol X, et al. Disseminated adiaspiromycosis: case report of a liver transplant patient with human immunodeficiency infection, and literature review. Transpl Infect Dis. 2011;13:507–14.PubMedCrossRefGoogle Scholar
  59. 59.
    Rosow L, Jiang JX, Deuel T, et al. Cerebral phaeohyphomycosis caused by Bipolaris spicifera after heart transplantation. Transpl Infect Dis. 2011;13:419–23.PubMedCrossRefGoogle Scholar
  60. 60.
    Lief MH, Caplivski D, Bottone EJ, Lerner S, Vidal C, Huprikar S. Exophiala jeanselmei infection in solid organ transplant recipients: report of two cases and review of the literature. Transpl Infect Dis. 2011;13:73–9.PubMedCrossRefGoogle Scholar
  61. 61.
    Zhang Y-Q, Xu X-G, Li F-Q, Wei H, Chen H-D, Li Y-H. Co-existence of cutaneous alternariosis and tinea corporis in a renal transplant recipient. Med Mycol. 2011;49:435–8.PubMedCrossRefGoogle Scholar
  62. 62.
    Rammaert B, Aguilar C, Bougnoux M-E, et al. Success of posaconazole therapy in a heart transplanted patient with Alternaria infectoria cutaneous infection. Med. Mycol. 2011; Available at: Accessed 2 April 2012.
  63. 63.
    Vignon M, Michonneau D, Baixench M-T, et al. Disseminated Scopulariopsis brevicaulis infection in an allogeneic stem cell recipient. Bone Marrow Transplant. 2011;46:1276–7.PubMedCrossRefGoogle Scholar
  64. 64.
    Ryan LJ, Ferrieri P, Powell Jr RD, Paddock CD, Zaki SR, Pambuccian SE. Fatal Cokeromyces recurvatus pneumonia: report of a case highlighting the potential for histopathologic misdiagnosis as coccidioides. Int J Surg Pathol. 2011;19:373–6.PubMedCrossRefGoogle Scholar
  65. 65.
    Spellberg B, Ibrahim A, Roilides E, et al. Combination Therapy for Mucormycosis: Why, What, and How? Clin Infect Dis. 2012;54:S73–8.PubMedCrossRefGoogle Scholar
  66. 66.
    Kontoyiannis DP. Invasive mycoses: strategies for effective management. Am J Med. 2012;125:S25–38.PubMedCrossRefGoogle Scholar
  67. 67.
    Troke P, Aguirrebengoa K, Arteaga C, et al. Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients. Antimicrob Agents Chemother. 2008;52:1743–50.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Perrine Parize
    • 1
  • Blandine Rammaert
    • 1
  • Olivier Lortholary
    • 1
    • 2
  1. 1.Université Paris-Descartes, Sorbonne Paris Cité, Hôpital Necker-Enfants Malades, Service des Maladies Infectieuses et Tropicales, APHP, Centre d’Infectiologie Necker-Pasteur, Institut Hospitalo-Universitaire ImagineParis Cedex 15France
  2. 2.Institut Pasteur, Centre National de Référence Mycoses Invasives et Antifongiques, CNRS URA3012ParisFrance

Personalised recommendations